ELOYA

Product screen

Evidence Explorer

Screenshot-ready product surface for enterprise review.

app.eloya.ai / evidence-explorer / KRAS-G12C-NSCLC
TL Translational Lead
KRAS G12C · NSCLC · Biomarker Strategy

Evidence Explorer

Reviewer status: 2/3 signed
1,284Evidence records
46Clinical trials
312Publications
18Biomarker notes
98%Traceability
Evidence ExplorerGraphReviewer QueueExports
Prioritized evidence tableUpdated 2026-06-18 · 10:42 UTC
EntityFindingSourceConfidenceReviewerTimestamp
KRAS G12CActionable mutation context in NSCLCPMID35658005HighSigned · Oncology10:42 UTC
AdagrasibTherapeutic evidence linked to G12CNCT03785249HighSigned · Clinical10:38 UTC
SotorasibComparator evidence for KRAS G12CNCT03600883Med-highPending · Translational10:33 UTC
MAPK pathwayMechanism and resistance contextPathway DBMediumQueued10:29 UTC
NSCLC cohortPatient-selection evidence summaryInternal memoNeeds reviewOpen10:21 UTC
Knowledge graphKRAS module · 9 linked nodes
KRASG12CNSCLCAdagrasibSotorasibMAPK
Reviewer statusDecision Review · v0.9

Clinical reviewer: signed evidence interpretation.

Oncology reviewer: signed biomarker rationale.

Translational reviewer: pending comparator review.

Model log attachedLineage completeExport locked
Audit trailPart 11-ready pattern
  • Evidence snapshot: 2026-06-18
  • Knowledge graph version: KG-KRAS-024
  • Prompt version: RAG-KG-014
  • Decision memo: awaiting final sign-off